Roivant Sciences Ltd. (ROIV) saw its stock price plummet by 5.13% in pre-market trading on Monday following the release of its disappointing first-quarter financial results for the fiscal year 2026. The biopharmaceutical company reported a wider-than-expected loss and a significant decline in revenue, causing investor concern.
For the quarter ended June 30, 2025, Roivant reported a net loss of $273.9 million, or $0.33 per share, compared to a net income of $95.3 million, or $0.13 per share, in the same period last year. The loss was larger than the FactSet analyst consensus estimate of a $0.28 loss per share. Revenue for the quarter fell sharply to $2.17 million, down from $8 million a year earlier and well below the $7.3 million analysts had expected.
Despite the disappointing results, Roivant's CEO Matt Gline emphasized the company's ongoing clinical progress and preparations for the potential launch of brepocitinib, a drug anticipated to benefit patients with high unmet needs. The company also reported a strong cash position of $4.5 billion, which it believes will support its operations into profitability. Additionally, Roivant completed a $1.5 billion share repurchase program and announced plans for a new $500 million buyback program. However, these positive aspects were overshadowed by the larger-than-expected quarterly loss, leading to the significant drop in stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.